These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 32244848)

  • 1. Availability of Authorizations from EMA and FDA for Age-Appropriate Medicines Contained in the WHO Essential Medicines List for Children 2019.
    delMoral-Sanchez JM; Gonzalez-Alvarez I; Gonzalez-Alvarez M; Navarro-Ruiz A; Bermejo M
    Pharmaceutics; 2020 Apr; 12(4):. PubMed ID: 32244848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Availability of Oral Formulations Labeled for Use in Young Children in Serbia, Germany and the USA.
    Bajcetic M; Kearns GL; Jovanovic I; Brajovic M; van den Anker JN
    Curr Pharm Des; 2015; 21(39):5668-73. PubMed ID: 26323413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orally disintegrating films and mini-tablets-innovative dosage forms of choice for pediatric use.
    Preis M
    AAPS PharmSciTech; 2015 Apr; 16(2):234-41. PubMed ID: 25739913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WHO essential medicines for children 2011-2019: age-appropriateness of enteral formulations.
    Orubu ESF; Duncan J; Tuleu C; Turner MA; Nunn A
    Arch Dis Child; 2022 Apr; 107(4):317-322. PubMed ID: 34479858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are age-appropriate antibiotic formulations missing from the WHO list of essential medicines for children? A comparison study.
    Ivanovska V; Leufkens HG; Rademaker CM; Zisovska E; Pijnenburg MW; van Dijk L; Mantel-Teeuwisse AK
    Arch Dis Child; 2017 Apr; 102(4):352-356. PubMed ID: 28119403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Providing Suitable Pediatric Formulations for Canadian Children: A Call for Action.
    Litalien C; Autmizguine J; Carli A; Giroux D; Lebel D; Leclerc JM; Théorêt Y; Gilpin A; Bérubé S
    Can J Hosp Pharm; 2020; 73(4):247-256. PubMed ID: 33100356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral medicines for children in the European paediatric investigation plans.
    van Riet-Nales DA; Römkens EG; Saint-Raymond A; Kozarewicz P; Schobben AF; Egberts TC; Rademaker CM
    PLoS One; 2014; 9(6):e98348. PubMed ID: 24897509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pediatric prescribing in tertiary care teaching hospital of Delhi (India): fragmenting medicines for use.
    Tayal H; Roy V; Singhal S; Dubey AP
    Eur J Pediatr; 2020 Sep; 179(9):1435-1443. PubMed ID: 32185474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does EU and US paediatric legislation improve the authorization availability of medicines for children in other countries?
    Volodina A; Shah-Rohlfs R; Jahn A
    Br J Clin Pharmacol; 2023 Mar; 89(3):1056-1066. PubMed ID: 36189466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EVALUATION OF CASES WITH THE USAGE OF COMMERCIALLY AVAILABLE TABLETS IN THE PEDIATRIC FORMULA.
    Kuriata E; Sawicki W
    Acta Pol Pharm; 2015; 72(3):551-8. PubMed ID: 26642663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paediatric Medicines - Regulatory Drivers, Restraints, Opportunities and Challenges.
    Vieira I; Sousa JJ; Vitorino C
    J Pharm Sci; 2021 Apr; 110(4):1545-1556. PubMed ID: 33421435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatrics Formulation Initiative: proceedings from the Second Workshop on Pediatric Formulations.
    Giacoia GP; Taylor-Zapata P; Zajicek A
    Clin Ther; 2012 Nov; 34(11):S1-10. PubMed ID: 23149008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Access to age-appropriate essential medicines: a retrospective survey of compounding of medicines for children in hospitals in Nigeria and implications for policy development.
    Orubu ES; Okwelogu C; Opanuga O; Nunn T; Tuleu C
    Health Policy Plan; 2017 Mar; 32(2):225-235. PubMed ID: 28207051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Availability of pediatric-evaluated formulations in Serbia.
    Božić B; Stupar S; Stupar D; Babić U; Bajčetić M
    Indian J Pharmacol; 2017; 49(2):189-193. PubMed ID: 28706333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crushability Analysis of Immediate-Release Oral Tablets and Capsules from the 2020-22 FDA Novel Drug Approvals.
    Saei K; Schweighardt A; Zhao F
    Int J Pharm Compd; 2024; 28(5):364-372. PubMed ID: 39405567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Registering medicines for low-income countries: how suitable are the stringent review procedures of the World Health Organisation, the US Food and Drug Administration and the European Medicines Agency?
    Doua JY; Van Geertruyden JP
    Trop Med Int Health; 2014 Jan; 19(1):23-36. PubMed ID: 24134396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neonatal and pediatric oral drug delivery: Hopes and hurdles.
    Mfoafo KA; Omidian M; Bertol CD; Omidi Y; Omidian H
    Int J Pharm; 2021 Mar; 597():120296. PubMed ID: 33524524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pediatric Oral Formulations: An Updated Review of Commercially Available Pediatric Oral Formulations Since 2007.
    Strickley RG
    J Pharm Sci; 2019 Apr; 108(4):1335-1365. PubMed ID: 30447227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acceptability of different oral dosage forms in paediatric patients in hospital setting.
    Pokharkar V; Sajith M; Vallet T; Akshantal S; Shah R; Ruiz F; Salunke S
    Arch Dis Child; 2022 Sep; 107(9):796-801. PubMed ID: 34799375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A proposed pediatric biopharmaceutical classification system for medications for chronic diseases in children.
    Bhatt-Mehta V; Hammoud H; Amidon GL
    Eur J Pharm Sci; 2020 Sep; 152():105437. PubMed ID: 32598914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.